OpenOnco
UA EN
Plan Builder Onco Wiki Tumor Board

Onco Wiki / Drug

Lenalidomide

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

IDDRUG-LENALIDOMIDE
TypeDrug
Aliases
RevlimidЛеналідомід
Statusreviewed 2026-04-26 | pending_clinical_signoff
DiseasesDIS-FL DIS-MDS-LR DIS-MM
SourcesSRC-NCCN-MM-2025

Drug Facts

Classimmunomodulator — IMiD (cereblon E3 ligase modulator)
MechanismBinds cereblon (CRBN) within the CRL4-CRBN E3 ubiquitin ligase complex, redirecting it to ubiquitinate IKZF1 and IKZF3 transcription factors. Their degradation is selectively cytotoxic to multiple myeloma cells and has immunomodulatory effects (NK and T-cell activation).
Typical dosing25 mg PO days 1-21 of 28-day cycle (induction); reduced for renal impairment
Ukraine registeredTrue
NSZU reimbursedTrue
Ukraine last verified2026-04-27

Warnings

Notes

Renal dose adjustment is critical: CrCl 30-60 mL/min → 10 mg daily; CrCl <30 (no dialysis) → 15 mg every other day; dialysis → 5 mg post- dialysis on dialysis days. VTE prophylaxis (aspirin 81-325 mg or LMWH in higher-risk patients) is mandatory throughout therapy.

Used By

Contraindications

Regimens